India, April 10 -- Pasithea Therapeutics Corp. (KTTA) surged 41.66% to $1.53 during Thursday's trading, gaining $0.45 after its external Safety Review Committee recommended advancing its Phase 1 clinical trial of PAS-004 in advanced cancer to Cohort 6 at a 30mg capsule dose without any protocol modifications.
The stock opened at $1.86 and has traded between $1.45 and $2.34 today, compared to a previous close of $1.08 on the Nasdaq. Trading volume soared to approximately 94.5 million shares, far above the average of about 1.1 million. The stock's 52-week range is $0.9230 to $8.11.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
This decision was based on the review of safety data from three patients in...